Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity

Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors

(2013) Mark E. Welker et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery

(2012) S. Karve et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Folate-Targeted Polymeric Nanoparticle Formulation of Docetaxel Is an Effective Molecularly Targeted Radiosensitizer with Efficacy Dependent on the Timing of Radiotherapy

(2011) Michael E. Werner et al.   ACS Nano

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

(2010) P. Workman et al.   CANCER RESEARCH

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Delivering nanomedicine to solid tumors

(2010) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors

(2009) B. Evers et al.   CLINICAL CANCER RESEARCH

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

(2008) Keith A. Menear et al.   JOURNAL OF MEDICINAL CHEMISTRY